New drug duo targets hidden leukemia before it returns
NCT ID NCT07264010
Summary
This study is testing whether a combination of two existing drugs, sorafenib and venetoclax, can safely eliminate small amounts of lingering leukemia cells in patients with acute myeloid leukemia (AML). The goal is to prevent the cancer from coming back in people who have already had treatment but still show signs of minimal disease. Researchers will measure how well the treatment clears these cells and monitor patients for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA (AML) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.